BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) was a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research. It went public in 1994 and moved its headquarters to Raleigh, North Carolina in 2010. It maintains a "Discovery Research Center and Laboratory Center of Excellence" in Birmingham.
Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
BioCryst merged with Idera Pharmaceuticals of Exton, Pennsylvania in 2018.
BioCryst has developed several drug treatments:
- Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
- Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
- Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
- Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
- BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
- Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
- BCX-4208 Oral, for treatment of Hepatitis C
- BioCryst Pharmaceuticals, Inc. (2005) Corporate Report 2005 (PDF) - accessed September 21, 2006
- BioCryst Pharmaceuticals Inc. corporate spotlight at NASDAQ. - accessed September 21, 2006
- Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." The Birmingham News
- DeButts, Jimmy (November 13, 2009) "BioCryst sees healthy future after flu drug." Birmingham Business Journal
- Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." Birmingham Business Journal
- Patchen, Tyler (January 23, 2018) "BioCryst Pharmaceuticals to merge with Pennsylvania pharmaceutical company." Birmingham Business Journal
- BioCryst Pharmaceuticals Inc. website